ORTX Stock Overview
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Orchard Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$16.70 |
52 Week High | US$16.72 |
52 Week Low | US$4.24 |
Beta | 0.55 |
1 Month Change | 1.71% |
3 Month Change | 4.57% |
1 Year Change | 188.88% |
3 Year Change | -70.28% |
5 Year Change | -86.41% |
Change since IPO | -88.07% |
Recent News & Updates
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Shareholder Returns
ORTX | US Biotechs | US Market | |
---|---|---|---|
7D | 0.9% | 0.9% | 0.4% |
1Y | 188.9% | 10.3% | 28.8% |
Return vs Industry: ORTX exceeded the US Biotechs industry which returned 7.5% over the past year.
Return vs Market: ORTX exceeded the US Market which returned 19% over the past year.
Price Volatility
ORTX volatility | |
---|---|
ORTX Average Weekly Movement | 0.6% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ORTX has not had significant price volatility in the past 3 months.
Volatility Over Time: ORTX's weekly volatility has decreased from 16% to 1% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 166 | Bobby Gaspar | https://www.orchard-tx.com |
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.
Orchard Therapeutics plc Fundamentals Summary
ORTX fundamental statistics | |
---|---|
Market cap | US$380.12m |
Earnings (TTM) | -US$72.92m |
Revenue (TTM) | US$21.84m |
17.4x
P/S Ratio-5.2x
P/E RatioIs ORTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ORTX income statement (TTM) | |
---|---|
Revenue | US$21.84m |
Cost of Revenue | US$79.52m |
Gross Profit | -US$57.68m |
Other Expenses | US$15.24m |
Earnings | -US$72.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.20 |
Gross Margin | -264.11% |
Net Profit Margin | -333.90% |
Debt/Equity Ratio | 31.9% |
How did ORTX perform over the long term?
See historical performance and comparison